Posts

Moderna adds commercial chief, expands Stephen Hoge's role

on

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Use AI and Real‑World Data to Improve Clinical Trial Success

on

Aspen Neuroscience's Personalized Parkinson's Therapy Shows Early Promise with 12-Month Data

on

AbbVie Invests $380 Million in Active Pharmaceutical Ingredient Manufacturing Expansion in North Chicago, Illinois

on

Biotech's New Cycle, JPM 2026 Deal Hype, and Hidden Alpha Opportunities

on

Eli Lilly Picks Houston for $6.5 Billion API Manufacturing Facility

on

AbbVie Buys Gilgamesh's Psychedelic Drug Bretisilocin for $1.2B

on

Reunion Psychedelic Therapy Advances to Pivotal Trials after Postpartum Depression Success

on

AbbVie Raises 2025 Guidance and Eyes Strategic Deals in Neuroscience, Obesity, and Oncology

on

Deal Roundup: Novartis Options Sironax's Neuro Platform, Plus Moves from Revolution, Iambic, Sernova, and Eledon

on

ALTO-203 Misses Depression Endpoint but Shows Positive Biomarker and Cognitive Signals

on

AbbVie Commits $335M Upfront in Landmark siRNA Deal With ADARx

on

Major Clinical Trial Failures of 2024: Setbacks in Neuroscience and Beyond

on

J&J's Swift $14.6B Acquisition of Intra-Cellular Therapies: A CEO-Driven Deal

on